Next Generation Cancer Diagnostics Market Size & Forecasts By Technology (NGS, LOAC & RT-PCR), By Application (CTC, Biomarker), By Cancer Type (Lung, Breast), By Function Companion Diagnostics), And Trend Analysis, 2013 - 2024

The global next generation cancer diagnostics market is anticipated to reach USD 11.04 billion by 2024, according to a new report by Grand View Research, Inc. Key drivers for this vertical include rising advancement in genomics and proteomics-based research coupled with increasing prevalence of oncology disorders.

Rise in number of oncological research projects to elucidate tumorigenesis and the underlying mechanisms, consequently raising the demand for serial sampling, diagnosis, and therapeutic manipulation, is a growth rendering driver of this market.

Further Key Findings from the Study Suggest:

The qPCR & multiplexing segment captured the largest market share in 2015 owing to the presence of a wide product portfolio serving numerous applications in oncology R&D

Next generation sequencing services and solutions for oncology applications are anticipated to be the fastest growing segment

Oncology diagnostics in biomarker discovery is expected witness growth as it subsequently facilitates drug designing and identification of novel targets against tumors

On the basis of cancer type, this vertical is segmented into lung, breast, colorectal, cervical, and other forms of cancer

Research projects to establish the therapeutic index of anticancer cytotoxic drugs are one of the key factors responsible for expected growth

North America dominated the market with respect to revenue generation in 2014 due to concerted efforts directed toward the development of next generation sequencing technology and companion diagnostics in personalized medicine

Some of the key players contributing significantly to the next generation cancer diagnostics market are Novartis AG; Cepheid; Hoffman La Roche Ltd.; PerkinElmer, Inc.; Sysmex Corporation; Abbott; Thermo Fisher Scientific, Inc.; Koninklijke Philips N.V.; Agilent Technologies; Illumina, Inc.; Genomic Health, Inc.; Qiagen; Janssen Global Services, LLC; Hologic, Inc.; Myriad Genetics, Inc.; Almac Group; Opko Health, Inc.; and GE Healthcare.

Table of Contents

Chapter 1 Executive Summary
Chapter 2 Next Generation Cancer Diagnostics Industry Outlook
2.1 Market segmentation
2.2 Market size and growth prospects, 2013 - 2024
2.3 Next generation cancer diagnostics market dynamics
2.3.1 Market driver analysis
2.3.1.1 Exponentially decreasing cost of genetic sequencing
2.3.1.2 Development of cluster chip technology and potential applications of CTC in cancer management
2.3.1.3 Rising demand for preventive medicine & companion diagnostics
2.3.1.4 Growing cancer incidence
2.3.2 Market restraint analysis
2.3.2.1 Requirement of expensive laboratory set-up for implementation of novel tests
2.4 Key Opportunities Prioritized
2.5 Industry analysis - Porter’s
2.6 Next Generation Cancer Diagnostics PESTEL Analysis
Chapter 3 Next Generation Cancer Diagnostics Technology Outlook
3.1 Global next generation cancer diagnostics revenue share, by technology, 2015 & 2024
3.2 NGS-based cancer diagnostics
3.2.1 NGS-based cancer diagnostics market, 2013 - 2024 (USD Million)
3.3 qPCR & Multiplexing
3.3.1 qPCR & multiplexing-based market, 2013 - 2024 (USD Million)
3.4 Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
3.4.1 LOAC & RT-PCR-based market, 2013 - 2024 (USD Million)
3.5 Protein microarrays-based cancer diagnostics
3.5.1 Protein microarraysmarket, 2013 - 2024 (USD Million)
3.6 DNA microarrays-based cancer diagnostics
3.6.1 DNAmicroarrays-based cancer diagnosticsmarket, 2013 - 2024 (USD Million)
Chapter 4 Next Generation Cancer Diagnostics Outlook by Cancer Type
4.1 Global next generation cancer diagnostics revenue share, by cancer type, 2015&2024
4.2 Lung cancer
4.2.1 NGCD for lung cancer market, 2013 - 2024 (USD Million)
4.3 Breast cancer
4.3.1 NGCD for breast cancer market, 2013 - 2024 (USD Million)
4.4 Colorectal cancer
4.4.1 NGCD for colorectal cancer market, 2013 - 2024 (USD Million)
4.5 Cervical cancer
4.5.1 NGCD for cervical cancer market, 2013 - 2024 (USD Million)
4.6 Other types of cancer
4.6.1 NGCD for other forms of cancer market, 2013 - 2024 (USD Million)
Chapter 5 Next Generation Cancer Diagnostics Outlook by Application Outlook
5.1 Global next generation cancer diagnostics revenue share, by application, 2015&2024
5.2 Biomarker development
5.2.1 NGCD for biomarker development market, 2013 - 2024 (USD Million)
5.3 CTC analysis
5.3.1 NGCD for CTC analysis market, 2013 - 2024 (USD Million)
5.4 Proteomic analysis
5.4.1 NGCD for proteomic analysis market, 2013 - 2024 (USD Million)
5.5 Epigenetic analysis
5.5.1 NGCD for epigenetic analysis market, 2013 - 2024 (USD Million)
5.6 Genetic analysis
5.6.1 NGCD for genetic analysismarket, 2013 - 2024 (USD Million)
Chapter 6 Next Generation Cancer Diagnostics Outlook by Function
6.1 Global next generation cancer diagnostics revenue share, by function, 2015&2024
6.2 Therapeutic monitoring
6.2.1 NGCD for therapeutic monitoring market, 2013 - 2024 (USD Million)
6.3 Companion diagnostics
6.3.1 NGCD for companion diagnostics market, 2013 - 2024 (USD Million)
6.4 Prognostic diagnostics
6.4.1 NGCD for prognostics market, 2013 - 2024 (USD Million)
6.5 Cancer screening
6.5.1 NGCD for cancer screening market, 2013 - 2024 (USD Million)
6.6 Risk analysis
6.6.1 NGCD for risk analysis market, 2013 - 2024 (USD Million)
Chapter 7 Next Generation Cancer Diagnostics Regional Outlook
7.1 Global next generation cancer diagnostics revenue share, by region, 2015 & 2024
7.2 North America
7.2.1 North America next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.2.2 U.S.
7.2.2.1 U.S. next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.2.3 Canada
7.2.3.1 Canada next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.3 Europe
7.3.1 Europe next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.3.2 Germany
7.3.2.1 Germany next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.3.3 France
7.3.3.1 France next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.4 Asia Pacific
7.4.1 Asia Pacific next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.4.2 Japan
7.4.2.1 Japan next generation cancer diagnosticsmarket, 2013 - 2024 (USD Million)
7.4.3 China
7.4.3.1 China next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.5 Latin America
7.5.1 Latin Americanext generation cancer diagnosticsmarket, 2013 - 2024 (USD Million)
7.5.2 Brazil
7.5.2.1 Brazil next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.6 MEA
7.6.1 MEA next generation cancer diagnostics market, 2013 - 2024 (USD Million)
7.6.2 South Africa
7.6.2.1 South Africa next generation cancer diagnostics market, 2013 - 2024 (USD Million)
Chapter 8 Competitive Landscape
8.1 Janssen Global Services, LLC
8.1.1 Company Overview
8.1.2 Financial Performance
8.1.3 Product Benchmarking
8.1.4 Strategic Initiatives
8.2 Novartis AG
8.2.1 Company Overview
8.2.2 Financial Performance
8.2.3 Product Benchmarking
8.2.4 Strategic Initiatives
8.3 F. Hoffmann-La Roche Ltd
8.3.1 Company Overview
8.3.2 Financial Performance
8.3.3 Product Benchmarking
8.3.4 Strategic Initiatives
8.4 Koninklijke Philips N.V.
8.4.1 Company Overview
8.4.2 Financial Performance
8.4.3 Product Benchmarking
8.4.4 Strategic Initiatives
8.5 Abbott
8.5.1 Company Overview
8.5.2 Financial Performance
8.5.3 Product Benchmarking
8.6 GE Healthcare
8.6.1 Company Overview
8.6.2 Financial Performance
8.6.3 Product Benchmarking
8.6.4 Strategic Initiatives
8.7 Thermo Fisher Scientific, Inc.
8.7.1 Company Overview
8.7.2 Financial Performance
8.7.3 Product Benchmarking
8.7.4 Strategic Initiatives
8.8 Agilent Technologies (Dako)
8.8.1 Company Overview
8.8.2 Financial Performance
8.8.3 Product Benchmarking
8.8.4 Strategic Initiatives
8.9 Illumina, Inc.
8.9.1 Company Overview
8.9.2 Financial Performance
8.9.3 Product Benchmarking
8.9.4 Strategic Initiatives
8.10 Qiagen
8.10.1 Company Overview
8.10.2 Financial Performance
8.10.3 Product Benchmarking
8.10.4 Strategic Initiatives
8.11 Cepheid
8.11.1 Company Overview
8.11.2 Financial Performance
8.11.3 Product Benchmarking
8.11.4 Strategic Initiatives
8.12 Opko Health, Inc.
8.12.1 Company Overview
8.12.2 Financial Performance
8.12.3 Service Benchmarking
8.12.4 Strategic Initiatives
8.13 Hologic, Inc (Gen-Probe)
8.13.1 Company Overview
8.13.2 Financial Performance
8.13.3 Product Benchmarking
8.13.4 Strategic Initiatives
8.14 Perkin Elmer, Inc.
8.14.1 Company Overview
8.14.2 Financial Performance
8.14.3 Product Benchmarking
8.14.4 Strategic Initiatives
8.15 Sysmex Corporation
8.15.1 Company Overview
8.15.2 Financial Performance
8.15.3 Product Benchmarking
8.15.4 Strategic Initiatives
8.16 Myriad Genetics, Inc.
8.16.1 Company Overview
8.16.2 Financial Performance
8.16.3 Product Benchmarking
8.16.4 Strategic Initiatives
8.17 Almac Group
8.17.1 Company Overview
8.17.2 Financial Performance
8.17.3 Product Benchmarking
8.17.4 Strategic Initiatives
8.18 Exosome Diagnostics, Inc.
8.18.1 Company Overview
8.18.2 Financial Performance
8.18.3 Product Benchmarking
8.18.4 Strategic Initiatives
8.19 Genomic Health, Inc.
8.19.1 Company Overview
8.19.2 Financial Performance
8.19.3 Product Benchmarking
8.19.4 Strategic Initiatives